Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Neubauer

Showing results (151-160 of 224) with videos related to

Pageof 23
Sort By:
The Oncologist|March 29, 2020
Renaissance of Radiotherapy in Intestinal Lymphoma? 10-Year Efficacy and Tolerance in Multimodal Treatment of 134 Patients: Follow-up of Two German Multicenter Consecutive Prospective Phase II TrialsGabriele Reinartz, Caroline Molavi Tabrizi, Ruediger Liersch, et al.
The Lancet. Haematology|March 19, 2018
Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trialFrederick Fasslrinner, Johannes Schetelig, Andreas Burchert, et al.
Cancers|April 27, 2024
NGS-Guided Precision Oncology in Breast Cancer and Gynecological Tumors-A Retrospective Molecular Tumor Board AnalysisNiklas Gremke, Fiona R Rodepeter, Julia Teply-Szymanski, et al.
Bone Marrow Transplantation|December 20, 2024
Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working PartyJesús Duque-Afonso, Jürgen Finke, Maud Ngoya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2013
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trialMarkus Schaich, Stefani Parmentier, Michael Kramer, et al.
Bone Marrow Transplantation|April 11, 2023
Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationIman Abou Dalle, Myriam Labopin, Nicolaus Kröger, et al.
Gastroenterology|May 2, 2002
T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradicationHongxiang Liu, Hongtao Ye, Agnes Ruskone-Fourmestraux, et al.
Blood|January 26, 2022
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trialAlexander E Perl, Richard A Larson, Nikolai A Podoltsev, et al.
The Lancet. Oncology|September 11, 2012
Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trialMartin Bornhäuser, Joachim Kienast, Rudolf Trenschel, et al.
American Journal of Hematology|May 23, 2024
Peripheral blood stem cell versus bone marrow graft for patients ≥60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationRaynier Devillier, Jacques-Emmanuel Galimard, Didier Blaise, et al.
Pageof 23

Showing results (151-160 of 224) with videos related to

Sort By:
Pageof 23
The Oncologist|March 29, 2020
Renaissance of Radiotherapy in Intestinal Lymphoma? 10-Year Efficacy and Tolerance in Multimodal Treatment of 134 Patients: Follow-up of Two German Multicenter Consecutive Prospective Phase II TrialsGabriele Reinartz, Caroline Molavi Tabrizi, Ruediger Liersch, et al.
The Lancet. Haematology|March 19, 2018
Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trialFrederick Fasslrinner, Johannes Schetelig, Andreas Burchert, et al.
Cancers|April 27, 2024
NGS-Guided Precision Oncology in Breast Cancer and Gynecological Tumors-A Retrospective Molecular Tumor Board AnalysisNiklas Gremke, Fiona R Rodepeter, Julia Teply-Szymanski, et al.
Bone Marrow Transplantation|December 20, 2024
Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working PartyJesús Duque-Afonso, Jürgen Finke, Maud Ngoya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2013
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trialMarkus Schaich, Stefani Parmentier, Michael Kramer, et al.
Bone Marrow Transplantation|April 11, 2023
Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationIman Abou Dalle, Myriam Labopin, Nicolaus Kröger, et al.
Gastroenterology|May 2, 2002
T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradicationHongxiang Liu, Hongtao Ye, Agnes Ruskone-Fourmestraux, et al.
Blood|January 26, 2022
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trialAlexander E Perl, Richard A Larson, Nikolai A Podoltsev, et al.
The Lancet. Oncology|September 11, 2012
Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trialMartin Bornhäuser, Joachim Kienast, Rudolf Trenschel, et al.
American Journal of Hematology|May 23, 2024
Peripheral blood stem cell versus bone marrow graft for patients ≥60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationRaynier Devillier, Jacques-Emmanuel Galimard, Didier Blaise, et al.
Pageof 23